You are about to leave the Clinical Value website now.

Cancel

Lung Cancer

Lung cancer is one of the most common forms of cancer, with 1.3 million people being diagnosed every year in APAC. Majority of these cases are diagnosed at late stages, when survival rates are low.

To ensure the best chances of survival, disease understanding, diagnostic testing, genomic profiling and clinical decision support solutions are key to early diagnosis and personalized treatment. Multidisciplinary partnership and innovation can provide the opportunity to improve the lives of millions of people around the world.

Expert Opinions

7 November 2023

Value and Challenges for Precision Oncology Realisation in Real World Practice

23 August 2023

NGS and precision oncology in Australia: insights from Profs Peter Gibbs and Svetlana Cherepanoff

In this article, Prof Peter Gibbs and Prof Svetlana Cherepanoff discuss the issues surrounding the clinical integration of NGS in Australia.

READ MORE
23 August 2023

NGS and precision oncology in Taiwan: insights from Dr Jan-Gowth Chang and Dr Jason CH Hsieh

NGS and digital applications for oncology management can help improve early cancer detection and prevention, reducing human and economic costs of the cancer. In this article,…

READ MORE
18 August 2023

NGS and precision oncology in India: insights from Dr Amit Rauthan

In this article, Dr Amit Rauthan shares insights on the challenges and opportunities for greater NGS adoption in India.

READ MORE
22 May 2023

NGS and precision oncology in Hong Kong: insights from Dr Lam Tai-Chung

In this article, Dr Lam Tai-Chung shares how his institution has had first-hand experience of landmark cases and outstanding treatment responses from using NGS in seemingly…

READ MORE
22 May 2023

Next-generation sequencing (NGS) drives precision oncology in Singapore

In this article, Dr David Tan discusses the potential of NGS in Singapore, where the adoption of this technology is only just beginning to take root.

READ MORE
22 May 2023

NGS and precision oncology in South Korea: insights from Prof Kim Jee-Hyun

In this article, Prof Jee Hyun Kim explains her clinical experiences of NGS, and how she sees it evolving within South Korea’s innovative healthcare ecosystem.

READ MORE
22 May 2023

Breaking barriers to precision oncology implementation with digital solutions

While precision oncology has shown great promise, there are still barriers to its implementation, such as data fragmentation, staff shortages and time, funding, and lack of…

READ MORE

Key Publications

18 August 2023

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia

This study aimed to evaluate the economic impact of upfront NGS compared to testing modalities in East Asian patients with mNSCLC, by using Hong Kong as…

READ MORE
17 August 2023

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

This study proposes a unified framework to classify targets for precision cancer medicine based on clinical evidence of utility, to aid oncologists in prioritising potential targets…

READ MORE
11 August 2023

The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours

The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular…

READ MORE
19 May 2023

Unlocking the Value of Quality Next-Generation Sequencing in APAC

The advancement of technology has created more opportunities for Next-Generation Sequencing (NGS). With greater public interest in Precision Medicine, it seems hopeful that NGS can potentially…

READ MORE
19 May 2023

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

This guideline aims to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the…

READ MORE
19 May 2023

National Comprehensive Cancer Network (NCCN) guidelines for lung cancer

The advancement of technology has created more opportunities for Next-Generation Sequencing (NGS). With greater public interest in Precision Medicine, it seems hopeful that NGS can potentially…

READ MORE
19 May 2023

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Non metastatic NSCLC in Asia

This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches…

READ MORE
19 May 2023

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

READ MORE
9 December 2022

APACMed White Paper – Strengthening Healthcare Systems Through the Critical Role of Diagnostics

Diagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite…

READ MORE

Webinars and Symposiums

The right tools at the right time: Liquid Biopsy enters the clinic

The field of clinical oncology continues to see drastic advancements with non-invasive techniques, such as liquid biopsy being adopted for diagnosing and monitoring cancers in place…

READ MORE

No time to wait: Evolving testing & treatment landscape in early stage lung cancer

Lung cancer has seen tremendous advancements over the past decade with the emergence of targeted therapies directed against mutant onco-proteins and immune checkpoint inhibitors. Join the…

READ MORE

ESMO Asia 2022 Singapore

Missed the satellite symposium sessions from ESMO Asia 2022? Access the webcast recordings here.

READ MORE

ESMO 2022 Paris

Missed the satellite symposium sessions from ESMO 2022? Access the webcast recordings here.

READ MORE

Value-based care in lung cancer: a case study from Belgium

To enable value-based healthcare, several important steps are needed. In this presentation and Q&A, Ingel Demedts discusses the project “Value-based care in lung cancer: a case…

READ MORE

Digital Tools to Drive NGS Clinical Application for the Future

The growing amount of clinical data available for each patient, clinicians need to manage massive genomic information, histological analysis tools, and clinical trials and publications. They…

READ MORE

Connecting Oncology and Pathology in the personalized care of NSCLC patients

Treatment landscape of NSCLC has been evolving dramatically in the past ten years, and biomarker testing is becoming increasingly complex. Join the webinar to hear from…

READ MORE

Clinical Utility of Liquid Biopsy in EGFR testing for Lung Cancer

Several EGFR tyrosine kinase inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations. While tissue biopsy samples continue to be the…

READ MORE

The importance of EGFR CDx testing and recent treatment updates in early stage NSCLC

Several EGFR Tyrosine Kinase Inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations. A robust and approved Companion Diagnostic (CDx) assay…

READ MORE

Lung Cancer Diagnostics Post COVID – a Multidisciplinary View

Various diagnostic tools play indispensable roles in diagnosing, staging, treatment selection & monitoring of lung cancer patients. Join the webinar to hear from pulmonologist Dr James…

READ MORE

Disease Awareness

Cancer genomic testing | Jennifer’s story

Comprehensive genomic profiling (CGP) is a method of cancer genomic testing used to reveal the unique set of mutations within the cancer’s DNA which determine how…

READ MORE

Be the first to receive updates, event opportunities, and thought leadership insights.